DK3663399T3 - Modificerede factor IX-polypeptider og anvendelser deraf - Google Patents

Modificerede factor IX-polypeptider og anvendelser deraf Download PDF

Info

Publication number
DK3663399T3
DK3663399T3 DK19218636.9T DK19218636T DK3663399T3 DK 3663399 T3 DK3663399 T3 DK 3663399T3 DK 19218636 T DK19218636 T DK 19218636T DK 3663399 T3 DK3663399 T3 DK 3663399T3
Authority
DK
Denmark
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
DK19218636.9T
Other languages
English (en)
Inventor
Edwin L Madison
Christopher Thanos
Grant Ellsworth Blouse
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Application granted granted Critical
Publication of DK3663399T3 publication Critical patent/DK3663399T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK19218636.9T 2010-11-03 2011-11-03 Modificerede factor IX-polypeptider og anvendelser deraf DK3663399T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45629810P 2010-11-03 2010-11-03
EP11781973.0A EP2635677B1 (en) 2010-11-03 2011-11-03 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
DK3663399T3 true DK3663399T3 (da) 2022-03-21

Family

ID=44936595

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11781973.0T DK2635677T3 (da) 2010-11-03 2011-11-03 Modificeret faktor IX-polypeptider og anvendelser deraf
DK19218636.9T DK3663399T3 (da) 2010-11-03 2011-11-03 Modificerede factor IX-polypeptider og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11781973.0T DK2635677T3 (da) 2010-11-03 2011-11-03 Modificeret faktor IX-polypeptider og anvendelser deraf

Country Status (18)

Country Link
US (4) US8778870B2 (da)
EP (2) EP2635677B1 (da)
JP (2) JP2013545457A (da)
KR (2) KR101841906B1 (da)
CN (1) CN103282491B (da)
AU (1) AU2011323295B2 (da)
BR (1) BR112013010834B1 (da)
CA (2) CA3129054A1 (da)
DK (2) DK2635677T3 (da)
ES (1) ES2782078T3 (da)
MX (2) MX345314B (da)
MY (2) MY162576A (da)
NZ (2) NZ609959A (da)
PH (1) PH12013500899A1 (da)
SG (2) SG10201510704PA (da)
TW (2) TWI595004B (da)
WO (1) WO2012061654A1 (da)
ZA (1) ZA201303134B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200502867B (en) * 2002-10-02 2007-09-26 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
EP2308967B1 (en) 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutant mt-sp1 polypeptides
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2337849B1 (en) 2008-09-15 2018-06-13 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
JP2015536148A (ja) * 2012-11-20 2015-12-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変第ｉｘ因子タンパク質についての方法および組成物
WO2014099850A1 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. FACTOR IXa 318R/A MUTANT
CN103060366A (zh) * 2012-12-25 2013-04-24 武汉科技大学 人凝血因子ⅸ突变体毕赤酵母表达载体及构建方法和应用
EP2881463A1 (en) * 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
AU2016302335B2 (en) * 2015-08-06 2022-08-04 The Trustees Of The University Of Pennsylvania GLP-1 and use thereof in compositions for treating metabolic diseases
EP4566666A3 (en) * 2016-07-27 2025-09-17 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
CN116732066A (zh) * 2016-10-14 2023-09-12 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
WO2018102743A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3617316A4 (en) * 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
US11491212B1 (en) * 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201817810D0 (en) * 2018-10-31 2018-12-19 Ucl Business Plc Modified factor IX polypeptides
WO2020160303A1 (en) 2019-02-01 2020-08-06 Baxalta Incorporated Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression
EP3941509B1 (en) * 2019-03-19 2025-12-03 CSL Innovation Pty Ltd Factor ix variants and uses thereof in therapy
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US20250312488A1 (en) * 2022-05-16 2025-10-09 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
CN120051296A (zh) * 2022-10-10 2025-05-27 杰特创新股份有限公司 用于施用到软组织的因子ix变体多肽
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides
WO2025143742A1 (ko) * 2023-12-26 2025-07-03 삼성바이오에피스 주식회사 혈액응고인자 IX를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
CA2074839C (en) 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE455552T1 (de) 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
MXPA02006216A (es) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Derivados estericamente impedidos de polimeros solubles en agua.
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
MXPA04001982A (es) * 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
ZA200502867B (en) 2002-10-02 2007-09-26 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
CA2788505C (en) 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
EP1620539A4 (en) 2003-05-05 2007-09-26 Monsanto Technology Llc TRANSGENIC PLANTS WITH INCREASED GLYCIN BETAIN
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
DE602004025576D1 (de) 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
EP1673453A2 (en) 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
EP2308967B1 (en) 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutant mt-sp1 polypeptides
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20080188400A1 (en) 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
US20090305967A1 (en) 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1991257B1 (en) 2006-03-07 2015-05-06 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor ix
HRP20160990T1 (hr) 2006-03-24 2016-10-07 Biogen Hemophilia Inc. Pc5 kao enzim obrade faktor ix propeptida
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8741096B2 (en) 2006-06-29 2014-06-03 Wonik Ips Co., Ltd. Apparatus for semiconductor processing
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
MX2009007146A (es) 2006-12-27 2009-07-09 Nektar Therapeutics Al Corp Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP1952822A1 (en) 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
EP2108046B9 (en) 2007-02-01 2014-03-26 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127702A2 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
RU2010146387A (ru) * 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP2337849B1 (en) 2008-09-15 2018-06-13 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
ES2524974T3 (es) 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof

Also Published As

Publication number Publication date
CA2816325C (en) 2022-08-23
KR101790589B1 (ko) 2017-10-27
CN103282491A (zh) 2013-09-04
KR20170054545A (ko) 2017-05-17
ZA201303134B (en) 2018-12-19
MY162576A (en) 2017-06-30
CA3129054A1 (en) 2012-05-10
WO2012061654A1 (en) 2012-05-10
KR101841906B1 (ko) 2018-03-26
TW201630932A (zh) 2016-09-01
US8778870B2 (en) 2014-07-15
SG190089A1 (en) 2013-06-28
EP3663399B1 (en) 2021-12-22
JP2013545457A (ja) 2013-12-26
AU2011323295B2 (en) 2015-05-28
JP6027221B2 (ja) 2016-11-16
MY192475A (en) 2022-08-23
CN103282491B (zh) 2016-08-24
US20140322191A1 (en) 2014-10-30
US20130177541A9 (en) 2013-07-11
NZ609959A (en) 2015-05-29
US20160201047A1 (en) 2016-07-14
DK2635677T3 (da) 2020-04-06
MX345314B (es) 2017-01-23
EP3663399A1 (en) 2020-06-10
NZ707439A (en) 2017-03-31
PH12013500899A1 (en) 2013-07-15
AU2011323295A1 (en) 2013-05-02
US9328339B2 (en) 2016-05-03
MX365396B (es) 2019-05-31
US20120308540A1 (en) 2012-12-06
BR112013010834B1 (pt) 2021-08-03
ES2782078T3 (es) 2020-09-10
TW201242975A (en) 2012-11-01
EP2635677A1 (en) 2013-09-11
BR112013010834A2 (pt) 2017-10-24
EP2635677B1 (en) 2020-01-01
US10982203B2 (en) 2021-04-20
MX2013004828A (es) 2013-08-29
JP2016116519A (ja) 2016-06-30
KR20130132833A (ko) 2013-12-05
TWI557135B (zh) 2016-11-11
US20210230570A1 (en) 2021-07-29
SG10201510704PA (en) 2016-01-28
CA2816325A1 (en) 2012-05-10
TWI595004B (zh) 2017-08-11

Similar Documents

Publication Publication Date Title
DK3663399T3 (da) Modificerede factor IX-polypeptider og anvendelser deraf
DK3572091T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
DK2552434T3 (da) Peptider og anvendelse deraf
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DK2536830T3 (da) Polypeptider
EP2593469A4 (en) MODIFIED POLYPEPTIDES AND PROTEINS AND ITS APPLICATION
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
SI3552619T1 (sl) Polipeptidi faktorja IX in načini njihove uporabe
DK3305492T3 (da) Kompositmaterialer og tilhørende fremgangsmåder
IL225897A0 (en) Cxcr2 binding polypeptides
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2544719T3 (da) Cd37-bindingsmolekyler og immunkonjugater deraf
PT2730564T (pt) Aminas heterocíclicas e suas utilizações
IL232247B (en) Polypeptide constructs and uses thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
IL226427A0 (en) Anti ccr4 antibodies and uses thereof
FR2963612B1 (fr) Element en treillis et grue
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
DK2642992T3 (da) Forbindelser og anvendelse deraf
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DE11786796T8 (de) Antigenpeptid und verwendung davon